AVTE Stock Price, Aerovate Therapeutics, . Quote, Chart

Market Summary

USD20.39-1.52

Delayedas of 17 May 2024, 12:55 pm

-6.94%

AVTE Alerts

4 major insider sales recently.

AVTE Stock Price

View Fullscreen

AVTE RSI Chart

AVTE Valuation

Market Cap

631.2M

Price/Earnings (Trailing)

-7.68

EV/EBITDA

-8.25

Price/Free Cashflow

-9.13

MarketCap/EBT

-8.36

AVTE Price/Earnings (Trailing)

AVTE Profitability

Return on Equity

-90.41%

Return on Assets

-76.94%

Free Cashflow Yield

-10.96%

AVTE Fundamentals

AVTE Earnings

Earnings (TTM)

-82.2M

Earnings Growth (Yr)

-40.35%

Earnings Growth (Qtr)

-13.58%

Breaking Down AVTE Revenue

52 Week Range

12.2921.86

(Low)(High)

Last 7 days

1.4%

Last 30 days

-7.4%

Last 90 days

4.5%

Trailing 12 Months

12.3%

How does AVTE drawdown profile look like?

AVTE Financial Health

Current Ratio

6.65

AVTE Investor Care

Shares Dilution (1Y)

15.59%

Diluted EPS (TTM)

-3.04

Tracking the Latest Insider Buys and Sells of Aerovate Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 02, 2024	verwijs marinus	sold	-41,630	21.015	-1,981	chief technical officer
May 01, 2024	noyes timothy p	acquired	21,400	2.14	10,000	chief executive officer
May 01, 2024	noyes timothy p	sold	-230,946	20.3351	-11,357	chief executive officer
Apr 17, 2024	gillies hunter	sold	-89,521	22.3805	-4,000	chief medical officer
Apr 17, 2024	gillies hunter	acquired	6,960	1.74	4,000	chief medical officer
Apr 17, 2024	dake benjamin t	acquired	14,665	2.14	6,853	see remarks
Apr 17, 2024	dake benjamin t	sold	-153,327	22.3737	-6,853	see remarks
Apr 16, 2024	noyes timothy p	sold	-246,971	24.6971	-10,000	chief executive officer
Apr 16, 2024	noyes timothy p	acquired	21,400	2.14	10,000	chief executive officer
Apr 10, 2024	eldridge george a	acquired	16,050	2.14	7,500	see remarks

Which funds bought or sold AVTE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Driehaus Capital Management LLC	reduced	-24.87	-439,357	23,507,900	0.23%
May 15, 2024	Sofinnova Investments, Inc.	unchanged	-	26,085,300	111,144,000	6.19%
May 15, 2024	Woodline Partners LP	new	-	5,914,000	5,914,000	0.05%
May 15, 2024	Octagon Capital Advisors LP	unchanged	-	2,801,570	11,937,000	1.43%
May 15, 2024	TCG Crossover Management, LLC	unchanged	-	15,276,800	65,091,700	5.15%
May 15, 2024	ORBIMED ADVISORS LLC	reduced	-25.31	-411,217	16,718,100	0.31%
May 15, 2024	FRED ALGER MANAGEMENT, LLC	added	20.04	469,373	1,294,870	0.01%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-60.71	-249,980	263,676	-%
May 15, 2024	MORGAN STANLEY	reduced	-25.02	-16,038	777,189	-%
May 15, 2024	STATE STREET CORP	added	7.46	1,957,260	6,800,690	-%

Are Funds Buying or Selling AVTE?

Are funds buying AVTE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AVTE

No. of Funds

AVTE Alerts

4 major insider sales recently.

Unveiling Aerovate Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 30, 2024	ra capital management, l.p.	28.9%	8,313,982	SC 13D/A
Feb 20, 2024	sofinnova venture partners x, l.p.	13.6%	3,758,686	SC 13D/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	citadel advisors llc	0.0%	6	SC 13G/A
Feb 14, 2024	baker bros. advisors lp	6.1%	1,680,517	SC 13G/A
Feb 09, 2024	tcg crossover gp i, llc	8.0%	2,201,274	SC 13G
Jun 27, 2023	ra capital management, l.p.	30%	8,293,148	SC 13D/A
Feb 14, 2023	citadel advisors llc	6.4%	6	SC 13G/A
Feb 14, 2023	cormorant asset management, lp	3.03%	745,436	SC 13G/A
Feb 14, 2023	baker bros. advisors lp	8.0%	1,976,868	SC 13G/A

Recent SEC filings of Aerovate Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 16, 2024	144	Notice of Insider Sale Intent
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 02, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
Apr 30, 2024	SC 13D/A	13D - Major Acquisition
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A

Peers (Alternatives to Aerovate Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Aerovate Therapeutics, Inc. News

Latest updates

Aerovate Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet													(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4
Assets	-16.2%	107	127	141	156	124	135	148	156	167	175	184	62.00	-
Current Assets	-16.9%	103	124	138	152	121	131	145	153	166	174	183	59.00	5.00
Cash Equivalents	-61.2%	9.00	23.00	32.00	61.00	27.00	22.00	22.00	27.00	28.00	54.00	181	59.00	5.00
Net PPE	-9.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	-11.4%	16.00	18.00	15.00	14.00	11.00	9.00	9.00	5.00	5.00	3.00	4.00	-	2.00
Current Liabilities	-12.0%	16.00	18.00	15.00	13.00	11.00	8.00	8.00	4.00	5.00	3.00	4.00	4.00	2.00
Shareholder's Equity	-16.9%	91.00	109	126	142	113	127	139	151	162	172	180	-	-
Retained Earnings	-14.2%	-186	-163	-143	-123	-104	-87.90	-72.88	-59.29	-47.30	-36.39	-28.17	-21.98	-13.41
Additional Paid-In Capital	1.8%	278	273	269	266	218	215	213	211	210	209	208	0.00	0.00
Shares Outstanding	0.4%	28.00	28.00	28.00	28.00	25.00	25.00	24.00	24.00	24.00	24.00	8.00	-	0.00
Float	-	-	-	-	232	-	-	-	157	-	-	-	185	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2
Cashflow From Operations	-60.0%	-23,673	-14,800	-15,611	-14,943	-11,424	-14,865	-9,720	-8,876	-5,661	-13,093	-6,526	-4,005	-3,775	-	-	-
Share Based Compensation	29.2%	4,200	3,251	3,237	3,034	2,384	1,729	1,499	1,224	1,024	854	845	321	23.00	-	-	-
Cashflow From Investing	56.4%	8,833	5,648	-13,130	3,983	15,375	14,486	4,645	8,194	-20,399	-113,338	-56.00	-	-40.00	-	-	-
Cashflow From Financing	1.7%	471	463	20.00	45,290	223	357	37.00	-	-	-250	128,310	54,514	7,883	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AVTE Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 20,080	$ 13,488
General and administrative	4,538	4,151
Total operating expenses	24,618	17,639
Loss from operations	(24,618)	(17,639)
Other income (expense):
Interest income	1,435	1,120
Other expense:	(3)	(1)
Total other income	1,432	1,119
Net loss	(23,186)	(16,520)
Comprehensive loss:
Net loss	(23,186)	(16,520)
Other comprehensive loss:
Unrealized (loss) gain on securities	(270)	265
Comprehensive loss	$ (23,456)	$ (16,255)
Net loss per share, basic	$ (0.83)	$ (0.67)
Net loss per share, diluted	$ (0.83)	$ (0.67)
Weighted-average shares of common stock outstanding, basic	27,795,827	24,777,847
Weighted-average shares of common stock outstanding, diluted	27,795,827	24,777,847

AVTE Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 9,122	$ 23,491
Short-term investments	90,212	98,948
Prepaid expenses and other current assets	3,905	1,793
Total current assets	103,239	124,232
Property and equipment, net	260	288
Operating lease right-of-use assets	725	614
Other long-term assets	2,597	2,284
Total assets	106,821	127,418
Current liabilities:
Accounts payable	3,313	2,396
Accrued and other current liabilities	11,760	14,821
Operating lease liabilities	445	420
Total current liabilities	15,518	17,637
Operating lease liabilities, net of current portion	329	255
Other liabilities	70	70
Total liabilities	15,917	17,962
Commitments and contingencies (Note 5)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 27,898,761 and 27,762,703 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	3	3
Additional paid-in capital	277,544	272,640
Accumulated other comprehensive (loss) income	(33)	237
Accumulated deficit	(186,610)	(163,424)
Total stockholders' equity	90,904	109,456
Total liabilities and stockholders' equity	$ 106,821	$ 127,418

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Timothy P. Noyes M.B.A.
WEBSITE	https://aerovatetx.com
INDUSTRY	Biotechnology
EMPLOYEES	43

Aerovate Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Aerovate Therapeutics, Inc.? What does AVTE stand for in stocks?

AVTE is the stock ticker symbol of Aerovate Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aerovate Therapeutics, Inc. (AVTE)?

As of Thu May 16 2024, market cap of Aerovate Therapeutics, Inc. is 631.19 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers.

What is the fair value of AVTE stock?

You can check AVTE's fair value in chart for subscribers. The fair value of Aerovate Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aerovate Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AVTE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aerovate Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether AVTE is over valued or under valued. Whether Aerovate Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Aerovate Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AVTE.